Related Experiment Video

Updated: Jun 25, 2026

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

Deep brain stimulation versus best medical therapy for advanced Parkinson's disease

Marwan Hariz

    The Lancet. Neurology
    |February 24, 2009
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Analysis of Gene Expression Changes in the Rat Hippocampus After Deep Brain Stimulation of the Anterior Thalamic Nucleus
    09:46

    Analysis of Gene Expression Changes in the Rat Hippocampus After Deep Brain Stimulation of the Anterior Thalamic Nucleus

    Published on: March 8, 2015

    Targeting Neuronal Fiber Tracts for Deep Brain Stimulation Therapy Using Interactive, Patient-Specific Models
    14:14

    Targeting Neuronal Fiber Tracts for Deep Brain Stimulation Therapy Using Interactive, Patient-Specific Models

    Published on: August 12, 2018

    Related Experiment Videos

    Last Updated: Jun 25, 2026

    Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
    11:12

    Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

    Published on: July 16, 2014

    Analysis of Gene Expression Changes in the Rat Hippocampus After Deep Brain Stimulation of the Anterior Thalamic Nucleus
    09:46

    Analysis of Gene Expression Changes in the Rat Hippocampus After Deep Brain Stimulation of the Anterior Thalamic Nucleus

    Published on: March 8, 2015

    Targeting Neuronal Fiber Tracts for Deep Brain Stimulation Therapy Using Interactive, Patient-Specific Models
    14:14

    Targeting Neuronal Fiber Tracts for Deep Brain Stimulation Therapy Using Interactive, Patient-Specific Models

    Published on: August 12, 2018

    Related Concept Videos

    Parkinson's Disease: Treatment01:24

    Parkinson's Disease: Treatment

    Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
    Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
    Parkinson's Disease: Overview01:15

    Parkinson's Disease: Overview

    Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

    Articles linked to this work by shared authors, journal, and citation graph.

    Artificial intelligence in deep brain stimulation for movement disorders: a systematic review and technology readiness assessment.

    NPJ digital medicine·2026

    Hardware Sophistications in Subthalamic Nucleus Deep Brain Stimulation for Parkinson's Disease; Is the Juice Worth the Squeeze?

    Movement disorders clinical practice·2026

    Observations on an Open-Label Phase 1/2 Dopamine Gene Therapy Trial (OXB-102/Axo-Lenti-PD) in People with Parkinson's Disease.

    Movement disorders : official journal of the Movement Disorder Society·2026

    Proton Density MR Imaging: A Simple and Powerful Sequence to Visualise Anatomical Structures in Functional Neurosurgery.

    Stereotactic and functional neurosurgery·2026

    Comparison of neuropsychological side effects between contemporary radiofrequency ablative neurosurgery for psychiatric disorders and conventional neurosurgical procedures: systematic review and meta-analysis.

    Journal of neurology, neurosurgery, and psychiatry·2026

    Alternative Deep Brain Stimulation Targets in the Treatment of Isolated Dystonic Syndromes: A Multicenter Experience-Based Survey.

    Movement disorders clinical practice·2025

    Prevalence of unruptured intracranial aneurysms according to comorbidities, risk factors, country, and time period: a systematic review and meta-analysis.

    The Lancet. Neurology·2026

    Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial.

    The Lancet. Neurology·2026

    Cholinesterase inhibitors in people with dementia with Lewy bodies and cardiac conduction abnormalities.

    The Lancet. Neurology·2026

    Advances in chronic subdural haematoma management: beyond the burr hole.

    The Lancet. Neurology·2026

    Antiseizure medication use in pregnancy and the risk of poor fetal growth in the EURAP international registry: a prospective cohort study.

    The Lancet. Neurology·2026

    Intensive blood pressure lowering after spontaneous intracerebral haemorrhage for secondary stroke prevention (RECAP-ICH): a systematic review and individual participant data meta-analysis.

    The Lancet. Neurology·2026

    Hematological neoplasms after PRRT: experience from long term follow-up of 173 patients in a tertiary center.

    Endocrine oncology (Bristol, England)·2026

    Comparative efficacy of free and PNAGA-encapsulated antimalarial drugs: temperature-dependent modulation of Plasmodium falciparum growth.

    Frontiers in pharmacology·2026

    Recent Advances in the Development of Novel Strategies for LongCirculating Drug Formulation.

    Current pharmaceutical biotechnology·2026

    Effect of a Ready-To-Use Vasopressin Product Availability in Automatic Dispensing Cabinets on Outcomes in Septic Shock.

    Journal of pharmacy practice·2026

    Importance of Single Global Regulatory Standards for the Assessment of Generic and Biosimilar Medicines to Advance Patient Access.

    The AAPS journal·2026

    Oral Janus nanomotor covalent conjugation rapeseed protein-derived DPP-IV inhibitory peptide and liraglutide: A self-propelled targeted delivery system for promoting insulin secretion and glucose-lowering.

    Food research international (Ottawa, Ont.)·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us